Abstract
Multiple sclerosis (MS) is a demyelinating and neurodegenerative disease of the central nervous system (CNS), most probably autoimmune in origin, usually occurring in young adults with a female/male prevalence of approximately 3:1. Women with MS in the reproductive age may face challenging issues in reconciling the desire for parenthood with their condition, owing to the possible influence both on the ongoing or planned treatment with the possible consequences on the disease course and on the potential negative effects of treatments on foetal and pregnancy outcomes. At MS diagnosis, timely counselling should promote informed parenthood, while disease evolution should be assessed before making therapeutic decisions. Current guidelines advise the discontinuation of any treatment during pregnancy, with possible exceptions for some treatments in patients with very active disease. Relapses decline during pregnancy but are more frequent during puerperium, when MS therapy should be promptly resumed in most of the cases. First-line immunomodulatory agents, such as interferon-β (IFN-β) and glatiramer acetate (GA), significantly reduce the post-partum risk of relapse. Due to substantial evidence of safety with the use of GA during pregnancy, a recent change in European marketing authorization removed the pregnancy contraindication for GA. This paper reports a consensus of Italian experts involved in MS management, including neurologists, gynaecologists and psychologists. This consensus, based on a review of the available scientific evidence, promoted an interdisciplinary approach to the management of pregnancy in MS women.
Similar content being viewed by others
Change history
26 December 2017
The original version contained a mistake. The authors have specified only in a few paragraphs that all the contents of the paper are meant for Copaxone but not for unbranded glatiramer acetate, Authors ask to add the specification of Copaxone or branded glatiramer acetate everytime.
References
Compston A, Coles A (2008) Multiple sclerosis. Lancet 372(9648):1502–1517. doi:10.1016/S0140-6736(08)61620-7
Bove R, Chitnis T (2014) The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Mult Scler 20(5):520–526. doi:10.1177/1352458513519181
Miller DH, Fazekas F, Montalban X, Reingold SC, Trojano M (2014) Pregnancy, sex and hormonal factors in multiple sclerosis. Mult Scler 20(5):527–536. doi:10.1177/1352458513519840
Pozzilli C, Pugliatti M, Paradig M. S. Group (2015) An overview of pregnancy-related issues in patients with multiple sclerosis. Eur J Neurol 22(Suppl 2):34–39. doi:10.1111/ene.12797
Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T (1998) Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 339(5):285–291. doi:10.1056/NEJM199807303390501
Vukusic S, Hutchinson M, Hours M, Moreau T, Cortinovis-Tourniaire P, Adeleine P, Confavreux C, Pregnancy In Multiple Sclerosis Group (2004) Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 127(Pt 6):1353–1360. doi:10.1093/brain/awh152
Karp I, Manganas A, Sylvestre MP, Ho A, Roger E, Duquette P (2014) Does pregnancy alter the long-term course of multiple sclerosis? Ann Epidemiol 24(7):504–508 e502. doi:10.1016/j.annepidem.2014.04.007
Masera S, Cavalla P, Prosperini L, Mattioda A, Mancinelli CR, Superti G, Chiavazza C, Vercellino M, Pinessi L, Pozzilli C (2015) Parity is associated with a longer time to reach irreversible disability milestones in women with multiple sclerosis. Mult Scler 21(10):1291–1297. doi:10.1177/1352458514561907
Jokubaitis VG, Spelman T, Kalincik T, Lorscheider J, Havrdova E, Horakova D, Duquette P, Girard M, Prat A, Izquierdo G, Grammond P, Van Pesch V, Pucci E, Grand'Maison F, Hupperts R, Granella F, Sola P, Bergamaschi R, Iuliano G, Spitaleri D, Boz C, Hodgkinson S, Olascoaga J, Verheul F, McCombe P, Petersen T, Rozsa C, Lechner-Scott J, Saladino ML, Farina D, Iaffaldano P, Paolicelli D, Butzkueven H, Lugaresi A, Trojano M, Group MSS (2016) Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Ann Neurol 80(1):89–100. doi:10.1002/ana.24682
Bove R, Alwan S, Friedman JM, Hellwig K, Houtchens M, Koren G, Lu E, McElrath TF, Smyth P, Tremlett H, Sadovnick AD (2014) Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. Obstet Gynecol 124(6):1157–1168. doi:10.1097/AOG.0000000000000541
Vukusic S, Marignier R (2015) Multiple sclerosis and pregnancy in the 'treatment era'. Nat Rev Neurol 11(5):280–289. doi:10.1038/nrneurol.2015.53
McCombe PA, Greer JM (2013) Female reproductive issues in multiple sclerosis. Mult Scler 19(4):392–402. doi:10.1177/1352458512452331
Pozzilli C, De Giglio L, Barletta VT, Marinelli F, Angelis FD, Gallo V, Pagano VA, Marini S, Piattella MC, Tomassini V, Pantano P (2015) Oral contraceptives combined with interferon beta in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2(4):e120. doi:10.1212/NXI.0000000000000120
Payne D, McPherson KM (2010) Becoming mothers. Multiple sclerosis and motherhood: a qualitative study. Disabil Rehabil 32(8):629–638. doi:10.3109/09638280903204708
Coyle PK (2016) Management of women with multiple sclerosis through pregnancy and after childbirth. Ther Adv Neurol Disord 9(3):198–210. doi:10.1177/1756285616631897
Ristori G, Cannoni S, Stazi MA, Vanacore N, Cotichini R, Alfo M, Pugliatti M, Sotgiu S, Solaro C, Bomprezzi R, Di Giovanni S, Figa Talamanca L, Nistico L, Fagnani C, Neale MC, Cascino I, Giorgi G, Battaglia MA, Buttinelli C, Tosi R, Salvetti M (2006) Multiple sclerosis in twins from continental Italy and Sardinia: a nationwide study. Ann Neurol 59(1):27–34. doi:10.1002/ana.20683
Sadovnick AD, Macleod PM (1981) The familial nature of multiple sclerosis: empiric recurrence risks for first, second-, and third-degree relatives of patients. Neurology 31(8):1039–1041
Coyle PK (2014) Multiple sclerosis and pregnancy prescriptions. Expert Opin Drug Saf 13(12):1565–1568. doi:10.1517/14740338.2014.973848
Ferrero S, Pretta S, Ragni N (2004) Multiple sclerosis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol 115(1):3–9. doi:10.1016/j.ejogrb.2003.10.020
Culpepper WJ 2nd (2015) The incidence and prevalence of comorbidity in multiple sclerosis. Mult Scler 21(3):261–262. doi:10.1177/1352458515574151
Food and Drug Administration (FDA) (2014) Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Available from: http://www.federalregister.gov/a/2014-28241. Accessed 26 November, 2016
European Medicines Agency (EMA) (2016) Quality review of documents human product-information annotated template (English) version 9. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2009/10/WC500004368.pdf. Accessed 26 November, 2016
National Institute for Health Care and Excellence (NICE) (2014) Multiple sclerosis in adults: management. Clinical guideline. Available from: https://www.nice.org.uk/guidance/cg186. Accessed 26 November 2016
Cavalla P, Rovei V, Masera S, Vercellino M, Massobrio M, Mutani R, Revelli A (2006) Fertility in patients with multiple sclerosis: current knowledge and future perspectives. Neurol Sci 27(4):231–239. doi:10.1007/s10072-006-0676-x
Michel L, Foucher Y, Vukusic S, Confavreux C, de Seze J, Brassat D, Clanet M, Clavelou P, Ouallet JC, Brochet B, Pelletier J, Labauge P, Lebrun C, Lepage E, Le Frere F, Jacq-Foucher M, Barriere P, Wiertlewski S, Laplaud DA, Club Francophone de la Sclerose En Plaques (2012) Increased risk of multiple sclerosis relapse after in vitro fertilisation. J Neurol Neurosurg Psychiatry 83(8):796–802. doi:10.1136/jnnp-2012-302235
Amato MP, Derfuss T, Hemmer B, Liblau R, Montalban X, Soelberg Sørensen P, Miller DH, for the 2016 ECTRIMS Focused Workshop Group (2017) Environmental modifiable risk factors for multiple sclerosis: report from the 2016 ECTRIMS focused workshop [epub ahead of print]. Multiple Sclerosis Journal:135245851668684. doi:10.1177/1352458516686847
Jalkanen A, Kauko T, Turpeinen U, Hamalainen E, Airas L (2015) Multiple sclerosis and vitamin D during pregnancy and lactation. Acta Neurol Scand 131(1):64–67. doi:10.1111/ane.12306
Munger KL, Aivo J, Hongell K, Soilu-Hanninen M, Surcel HM, Ascherio A (2016) Vitamin D status during pregnancy and risk of multiple sclerosis in offspring of women in the Finnish Maternity Cohort. JAMA Neurol 73(5):515–519. doi:10.1001/jamaneurol.2015.4800
ACOG American College of Obstetricians and Gynecologists (2011) Committee opinion no. 495: vitamin D: screening and supplementation during pregnancy. Obstet Gynecol 118(1):197–198
Greenberg JA, Bell SJ, Ausdal WV (2008) Omega-3 fatty acid supplementation during pregnancy. Rev Obstet Gynecol 1(4):162–169
Mueller BA, Zhang J, Critchlow CW (2002) Birth outcomes and need for hospitalization after delivery among women with multiple sclerosis. Am J Obstet Gynecol 186(3):446–452
Ponsonby AL, Lucas RM, van der Mei IA, Dear K, Valery PC, Pender MP, Taylor BV, Kilpatrick TJ, Coulthard A, Chapman C, Williams D, McMichael AJ, Dwyer T (2012) Offspring number, pregnancy, and risk of a first clinical demyelinating event: the AusImmune Study. Neurology 78(12):867–874. doi:10.1212/WNL.0b013e31824c4648
Pasto L, Portaccio E, Ghezzi A, Hakiki B, Giannini M, Razzolini L, Piscolla E, De Giglio L, Pozzilli C, Paolicelli D, Trojano M, Marrosu MG, Patti F, La Mantia L, Mancardi GL, Solaro C, Totaro R, Tola MR, Di Tommaso V, Lugaresi A, Moiola L, Martinelli V, Comi G, Amato MP, M. S. Study Group of the Italian Neurological Society (2012) Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurol 12:165. doi:10.1186/1471-2377-12-165
Kelly VM, Nelson LM, Chakravarty EF (2009) Obstetric outcomes in women with multiple sclerosis and epilepsy. Neurology 73(22):1831–1836. doi:10.1212/WNL.0b013e3181c3f27d
Banwell B, Giovannoni G, Hawkes C, Lublin F (2013) Editors' welcome and a working definition for a multiple sclerosis cure. Mult Scler Relat Disord 2(2):65–67. doi:10.1016/j.msard.2012.12.001
Kappos L, De Stefano N, Freedman MS, Cree BA, Radue EW, Sprenger T, Sormani MP, Smith T, Haring DA, Piani Meier D, Tomic D (2016) Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler 22(10):1297–1305. doi:10.1177/1352458515616701
Baroncini D, Ghezzi A, Annovazzi PO, Colombo B, Martinelli V, Minonzio G, Moiola L, Rodegher M, Zaffaroni M, Comi G (2016) Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. Mult Scler 22(10):1315–1326. doi:10.1177/1352458516650736
Sellebjerg F, Barnes D, Filippini G, Midgard R, Montalban X, Rieckmann P, Selmaj K, Visser LH, Sorensen PS, Relapses ETFoToMS (2005) EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol 12(12):939–946. doi:10.1111/j.1468-1331.2005.01352.x
Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hemmer B, Hartung HP, Havrdova E, Kappos L, Liblau R, Lubetzki C, Miller DH, Olsson T, Selmaj C, Siva A, Sorensen PS, Thalheim C, Wiendl H, Zipp F, Thompson AJ, Gold R, Montalban X (2016) ECTRIMS-EAN clinical practice guideline on pharmacological management of multiple sclerosis [abstract] . Multiple sclerosis journal 22(abstract 255):834
Leone MA, Keindl M, Schapira AH, Deuschl G, Federico A (2015) Practical recommendations for the process of proposing, planning and writing a neurological management guideline by EAN task forces. Eur J Neurol 22(12):1505–1510. doi:10.1111/ene.12818
Amato MP, Portaccio E, Ghezzi A, Hakiki B, Zipoli V, Martinelli V, Moiola L, Patti F, La Mantia L, Mancardi GL, Solaro C, Tola MR, Pozzilli C, De Giglio L, Totaro R, Lugaresi A, Di Tommaso V, Paolicelli D, Marrosu MG, Comi G, Pellegrini F, Trojano M, Society MSSGotIN (2010) Pregnancy and fetal outcomes after interferon-beta exposure in multiple sclerosis. Neurology 75(20):1794–1802. doi:10.1212/WNL.0b013e3181fd62bb
De Giglio L, Gasperini C, Tortorella C, Trojano M, Pozzilli C (2015) Natalizumab discontinuation and disease restart in pregnancy: a case series. Acta Neurol Scand 131(5):336–340. doi:10.1111/ane.12364
Giannini M, Portaccio E, Ghezzi A, Hakiki B, Pasto L, Razzolini L, Piscolla E, De Giglio L, Pozzilli C, Paolicelli D, Trojano M, Marrosu MG, Patti F, La Mantia L, Mancardi G, Solaro C, Totaro R, Tola MR, De Luca G, Lugaresi A, Moiola L, Martinelli V, Comi G, Amato MP (2012) Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol 12:124. doi:10.1186/1471-2377-12-124
Pecori C, Giannini M, Portaccio E, Ghezzi A, Hakiki B, Pasto L, Razzolini L, Sturchio A, De Giglio L, Pozzilli C, Paolicelli D, Trojano M, Marrosu MG, Patti F, Mancardi GL, Solaro C, Totaro R, Tola MR, De Luca G, Lugaresi A, Moiola L, Martinelli V, Comi G, Amato MP, Society MSSGotIN (2014) Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurol 14:114. doi:10.1186/1471-2377-14-114
Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H (2012) Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology 79(11):1130–1135. doi:10.1212/WNL.0b013e3182698c64
MHRA-Medicine & Health products Regulatory Agency (2016) Summary of product characteristics, Copaxone 20 mg/ml solution for injection, pre-filled syringe, revision 02/12/2016. Available from: http://www.mhra.gov.uk/. Accessed 31 January, 2017
MHRA-Medicine & Health products Regulatory Agency (2017) Summary of product characteristics, Copaxone 40 mg/ml solution for injection, pre-filled syringe, revision 30/03/2017. Available from: http://www.mhra.gov.uk/. Accessed 04 April, 2017
Vukusic S, Durand-Dubief F, Benoit A, Marignier R, Frangoulis B, Confavreux C (2015) Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis. Mult Scler 21(7):953–955. doi:10.1177/1352458514554056
Haghikia A, Langer-Gould A, Rellensmann G, Schneider H, Tenenbaum T, Elias-Hamp B, Menck S, Zimmermann J, Herbstritt S, Marziniak M, Kumpfel T, Meinl I, Plavina T, Gold R, Hellwig K (2014) Natalizumab use during the third trimester of pregnancy. JAMA Neurol 71(7):891–895. doi:10.1001/jamaneurol.2014.209
Gandhi S, Jakimovski D, Ahmed R, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R (2016) Use of natalizumab in multiple sclerosis: current perspectives. Expert Opin Biol Ther 16(9):1151–1162. doi:10.1080/14712598.2016.1213810
Friend S, Richman S, Bloomgren G, Cristiano LM, Wenten M (2016) Evaluation of pregnancy outcomes from the Tysabri(R) (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol 16(1):150. doi:10.1186/s12883-016-0674-4
Thiel S, Langer-Gould A, Rockhoff M, Haghikia A, Queisser-Wahrendorf A, Gold R, Hellwig K (2016) Interferon-beta exposure during first trimester is safe in women with multiple sclerosis—a prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler 22(6):801–809. doi:10.1177/1352458516634872
Comi G, Amato MP, Bertolotto A, Centonze D, De Stefano N, Farina C, Gallo P, Ghezzi A, Grimaldi LM, Mancardi G, Marrosu MG, Montanari E, Patti F, Pozzilli C, Provinciali L, Salvetti M, Tedeschi G, Trojano M (2016) The heritage of glatiramer acetate and its use in multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders 1(1):6. doi:10.1186/s40893-016-0010-2
Martinelli V, Colombo B, Dalla Costa G, Dalla Libera D, Moiola L, Falini A, Comi G, Filippi M (2016) Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning. Mult Scler 22(11):1506–1508. doi:10.1177/1352458513492246
Houtchens MK, Kolb CM (2013) Multiple sclerosis and pregnancy: therapeutic considerations. J Neurol 260(5):1202–1214. doi:10.1007/s00415-012-6653-9
Carmichael SL, Shaw GM, Ma C, Werler MM, Rasmussen SA, Lammer EJ, National Birth Defects Prevention Study (2007) Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 197(6):585 e581–585 e587. doi:10.1016/j.ajog.2007.05.046
Simon JH, Li D, Traboulsee A, Coyle PK, Arnold DL, Barkhof F, Frank JA, Grossman R, Paty DW, Radue EW, Wolinsky JS (2006) Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol 27(2):455–461
World Health Organization (2006) Pregnancy, childbirth, postpartum and newborn care. A guide for essential practice, World Health Organization (WHO) Department of Making Pregnancy Safer Geneva, Switzerland
Finkelsztejn A, Brooks JB, Paschoal FM Jr, Fragoso YD (2011) What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature. BJOG 118(7):790–797. doi:10.1111/j.1471-0528.2011.02931.x
Pakpoor J, Disanto G, Lacey MV, Hellwig K, Giovannoni G, Ramagopalan SV (2012) Breastfeeding and multiple sclerosis relapses: a meta-analysis. J Neurol 259(10):2246–2248. doi:10.1007/s00415-012-6553-z
Conradi S, Malzahn U, Paul F, Quill S, Harms L, Then Bergh F, Ditzenbach A, Georgi T, Heuschmann P, Rosche B (2013) Breastfeeding is associated with lower risk for multiple sclerosis. Mult Scler 19(5):553–558. doi:10.1177/1352458512459683
Fares J, Nassar AH, Gebeily S, Kobeissy F, Fares Y (2016) Pregnancy outcomes in Lebanese women with multiple sclerosis (the LeMS study): a prospective multicentre study. BMJ Open 6(5):e011210. doi:10.1136/bmjopen-2016-011210
Hellwig K, Rockhoff M, Herbstritt S, Borisow N, Haghikia A, Elias-Hamp B, Menck S, Gold R, Langer-Gould A (2015) Exclusive breastfeeding and the effect on postpartum multiple sclerosis relapses. JAMA Neurol 72(10):1132–1138. doi:10.1001/jamaneurol.2015.1806
Ragnedda G, Leoni S, Parpinel M, Casetta I, Riise T, Myhr KM, Wolfson C, Pugliatti M (2015) Reduced duration of breastfeeding is associated with a higher risk of multiple sclerosis in both Italian and Norwegian adult males: the EnvIMS study. J Neurol 262(5):1271–1277. doi:10.1007/s00415-015-7704-9
Amato MP, Portaccio E (2015) Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs. CNS Drugs 29(3):207–220. doi:10.1007/s40263-015-0238-y
Ford CC, Johnson KP, Lisak RP, Panitch HS, Shifronis G, Wolinsky JS, Copaxone Study Group (2006) A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 12(3):309–320. doi:10.1191/135248506ms1318oa
Portaccio E, Ghezzi A, Hakiki B, Sturchio A, Martinelli V, Moiola L, Patti F, Mancardi GL, Solaro C, Tola MR, Pozzilli C, De Giglio L, Totaro R, Lugaresi A, De Luca G, Paolicelli D, Marrosu MG, Comi G, Trojano M, Amato MP, M. S. Study Group of the Italian Neurological Society (2014) Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. J Neurol Neurosurg Psychiatry 85(8):845–850. doi:10.1136/jnnp-2013-306054
Alwan S, Yee IM, Dybalski M, Guimond C, Dwosh E, Greenwood TM, Butler R, Sadovnick AD (2013) Reproductive decision making after the diagnosis of multiple sclerosis (MS). Mult Scler 19(3):351–358. doi:10.1177/1352458512452920
Ferraro D, Simone AM, Adani G, Vitetta F, Mauri C, Strumia S, Senesi C, Curti E, Baldi E, Santangelo M, Montepietra S, Immovilli P, Guareschi A, Neri W, Granella F, Caniatti L, Tola MR, Motti L, Pesci I, Montanari E, Sola P (2017) Definitive childlessness in women with multiple sclerosis: a multicenter study. Neurol Sci. doi:10.1007/s10072-017-2999-1
Acknowledgements
We thank Luisa Granziero and Ray Hill, independent medical writers, who provided editorial assistance, respectively, in manuscript drafting and in English-language editing and journal styling prior to submission. This assistance was funded by Teva.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
Maria Pia Amato has received research grants and honoraria as a speaker and member of advisory boards from Bayer, Biogen, Merck, Novartis, Roche, Sanofi Genzyme and Teva. Paola Cavalla has received speaker honoraria and honoraria for serving on advisory board activities from Almirall, Biogen, Merck Serono, Novartis, Sanofi Genzyme and Teva. Giancarlo Comi has received compensation for consulting services and/or speaking activities from Teva, Novartis, Sanofi, Genzyme, Merck, Biogen, Roche, Almirall, Receptos, Celgene, Forward Pharma and Excemed. Maria Giovanna Marrosu has received speaker honoraria and honoraria for serving on advisory board activities from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Genzyme, Sanofi Aventis and Teva and research grants from Merck Serono and Novartis. Francesco Patti has received fees for consulting and/or advisory board activities from Almirall, Bayer, Biogen, Celgene, Merck, Novartis, Roche, Sanofi Genzyme and Teva. All other authors declare no conflict of interest.
Additional information
A correction to this article is available online at https://doi.org/10.1007/s10072-017-3226-9.
Rights and permissions
About this article
Cite this article
Amato, M.P., Bertolotto, A., Brunelli, R. et al. Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. Neurol Sci 38, 1849–1858 (2017). https://doi.org/10.1007/s10072-017-3081-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-017-3081-8